Key Highlights

  • ALVO shares rose 6.96% to $6.15 at Monday's close on September 28, 2026, while the Russell 2000 slipped 0.69%.
  • Alvotech develops and manufactures biosimilars, lower-cost follow-on versions of complex biologic medicines that have lost exclusivity.
  • Investor attention has stayed on its Biosimilars pipeline, and the stock rose even as the broader market fell.
  • Several other biotech names also finished higher on the day, including Liquidia, MBX Biosciences and NewAmsterdam Pharma.

Shares of Alvotech (NASDAQ:ALVO) ended Monday, September 28, 2026 higher by 6.96%, at $6.15. The biotechnology company develops and manufactures biosimilars, lower-cost follow-on versions of complex biologic medicines that have lost exclusivity.

Latest Developments

ALVO shares rose at Monday's close even as the broader US market fell.

Alvotech is a biotechnology company focused on developing and Manufacturing biosimilars, which are lower-cost follow-on versions of complex biologic medicines.

Financial and Business Position

Investor attention has stayed on its biosimilars pipeline.

Development-stage and specialty biotech names are often sensitive to rising yields, since much of their value rests on cash flows expected well into the future, yet Alvotech managed to rise anyway. Biosimilar development carries meaningful risk: regulatory decisions can slip, manufacturing inspections and quality matters can affect timelines, and even approved biosimilars face competitive and pricing pressure in crowded markets. Investors watching the name will typically weigh the number and timing of pending US decisions, the breadth of the pipeline across therapeutic areas, the company’s manufacturing readiness, and its path toward sustained profitability.

Stock-Market Context

The Nasdaq Composite led the declines on Monday, falling 0.92% to 26,820.38, while the S&P 500 lost 0.77% to 7,683.69 and the Dow Jones Industrial Average slipped 0.67% to 51,481.51. The Russell 2000 declined 0.69%.

Higher long-dated yields and firmer oil prices, tied to stalled US-Iran talks, set the tone: the 10-year Yield moved above 5.2%, a level last seen in 2007.

Several other biotech names also finished higher.

A Biosimilars Pipeline in a Down Market

Alvotech closed Monday higher while the indexes fell. Its biosimilars development and manufacturing model frames the stock.